The Medical Advisor

Cancer treatment has transformed dramatically over the past decade. From chemotherapy and radiation to targeted therapies, each advance has sought to tip the balance in favor of the patient. Now, cell-based immunotherapies — therapies that harness and engineer the body’s immune system to fight cancer — are taking center stage. Two of the most promising approaches are CAR-T and CAR-NK cell therapies. But what makes them different, and how are emerging innovations, including AI and NK cell expansion, shaping the future of immunotherapy? Understanding CAR-T Therapy CAR-T (Chimeric Antigen Receptor T-cell) therapy involves harvesting a patient’s T cells, genetically engineering them to recognize specific cancer antigens, and reinfusing them into the body. These modified T cells can detect and destroy cancer cells with remarkable precision. Strengths of CAR-T: High efficacy in blood cancers: Durable remissions have been reported in leukemia and lymphoma patients. Long-term immune memory: ...

CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer. CAR-T Cell Therapy Industry In 1987, Israeli immunologist Dr. Zelig Eshhar from the Weizmann Institute of Science developed the first “chimeric antigen receptor” (CAR), laying the foundation for modern CAR-T cell therapy. CARs are synthetic, engineered receptor proteins designed in the laboratory and do not exist naturally in the human body. Chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient’s own T cells to express these engineered receptors, e...